"The HTA device was carefully designed to be a safe and thorough method of ablating the uterine lining responsible for menorrhagia," said Stephen Corson, M.D., Professor of Obstetrics and Gynecology at Thomas Jefferson University School of Medicine and the study's director. "I believe more doctors will offer this option to their patients as an alternative to hysterectomy as they become aware of these results."

The HTA system was developed to reduce or eliminate excessive menstrual bleeding due to benign causes. The technique, approved by the U.S. Food and Drug Administration, employs rigorous safety measures and can be performed in a physician's office. The 10-minute, outpatient procedure requires no incisions and can be an alternative treatment to hysterectomy. Local anesthesia is administered to the patient before a hysteroscopic sheath is inserted through the cervical canal and into the uterine cavity. The cervix forms a seal around the sheath and heated saline is allowed to circulate freely throughout the uterus to ablate the lining responsible for menorrhagia. The procedure can be viewed on a monitor through the use of a hysteroscope.

Twenty years of research has shown that some endometrial ablation techniques have various problems with often undesired consequences. An article in The Journal of the American Association of Gynecologic Laparoscopists states that some other methods "can be difficult to learn and frequently result in incomplete ablation. In addition, use of nonphysiologic distending solutions ... may result in fluid overload." The HTA system is a simple alternative that has provided safe and effective results.

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties.

This press release contains forward-looking statements. The Company wishes to caution the reader of this press release that actual results may differ from those discussed in the forward-looking statements and may be adversely affected by, among other things, competitive offerings, intellectual property and other factors described in the Company's filings with the Securities and Exchange Commission.